Management Team
Henrik Otendal,
Chief Executive
Henrik Otendal has a financial background and extensive experience in senior positions across various industries. He is active as a board member and advisor in several companies within different sectors such as the automotive industry, Medtech, and shipping. He is also involved in Junior Achievement (UF) and has led initiatives in sustainability, gender equality, female entrepreneurship, and board work. Henrik Otendal is a co-founder of Reselo AB, an innovation company focused on the development and production of high-performance bio-based materials such as Reselo Rubber, an alternative to synthetic fossil-based rubber.
Lars Bruce,
Vice President Neurodegeneration - ILB®
VP and Board Member and founder of TikoMed. Lars is leading the research and development program for ILB®, our drug candidate for neurodegenerative diseases currently in clinical development for Amyotrophic Lateral Sclerosis (ALS).
Johan Olsson,
Chief Financial Officer
Johan holds a Master Degree of Business Administration from Lund University and specializes in accounting and auditing. Johan has previously worked at Nyström & Partners Revision AB, BJT Consulting AB and Personal Accounting Sweden AB.
Florence Lange,
Senior Coordinator - ILB®
Senior Coordinator for ILB project with more than 30 years’ experience as a Management- and Executive assistant and the expertise of working in a growing company from early stage to major international presence. Before joining TikoMed, Florence was involved in building up the organization and the administrative structure of an international start-up project.
Sten Kornfält,
Project Leader
Sten holds a pharmacy degree from Uppsala University and is a certified project manager. Sten has extensive experience in research, pharmaceutical development and the pharmaceutical industry and has most recently worked as project manager in different small biotech companies and clinical CROs.
Anita Tocaj,
Head of Regulatory Affairs
Anita holds a PhD in Biotechnology at Lund University. She has extensive experience from regulatory work from both as a consultant for CRO companies as well as from small pharma.
Marie Trad,
Chief Medical Officer
Dr. Trad is a board-certified Neurologist and a qualified Neuroradiologist from the Pierre and Marie Curie University, Paris, France. After over a decade of clinical practice, Marie joined the Pharmaceutical industry in 2000 where she has occupied different senior and strategic roles both in Pharma and CRO, spanning from head of the Eu Neurology medical group to head of the CNS unit dedicated to Biotechs.